Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2006 5
2007 5
2008 6
2009 6
2010 4
2011 3
2012 4
2013 9
2014 4
2015 3
2016 11
2017 10
2018 8
2019 8
2020 14
2021 13
2022 20
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Feagan BG, et al. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734. N Engl J Med. 2013. PMID: 23964932 Free article. Clinical Trial.
Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Sandborn WJ, et al. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739. N Engl J Med. 2013. PMID: 23964933 Free article. Clinical Trial.
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: jahnsen j. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: jahnsen j. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Free PMC article. Clinical Trial.
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Peyrin-Biroulet L, et al. Among authors: jahnsen j. BMC Gastroenterol. 2022 Jun 8;22(1):291. doi: 10.1186/s12876-022-02347-1. BMC Gastroenterol. 2022. PMID: 35676620 Free PMC article.
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK; NOR-SWITCH study group. Jørgensen KK, et al. Among authors: jahnsen j. Lancet. 2017 Jun 10;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5. Epub 2017 May 11. Lancet. 2017. PMID: 28502609 Clinical Trial.
Systemic Inflammation in Preclinical Ulcerative Colitis.
Bergemalm D, Andersson E, Hultdin J, Eriksson C, Rush ST, Kalla R, Adams AT, Keita ÅV, D'Amato M, Gomollon F, Jahnsen J; IBD Character Consortium; Ricanek P, Satsangi J, Repsilber D, Karling P, Halfvarson J. Bergemalm D, et al. Among authors: jahnsen j. Gastroenterology. 2021 Nov;161(5):1526-1539.e9. doi: 10.1053/j.gastro.2021.07.026. Epub 2021 Jul 21. Gastroenterology. 2021. PMID: 34298022 Free article.
Identification of gluten T cell epitopes driving celiac disease.
Chlubnová M, Christophersen AO, Sandve GKF, Lundin KEA, Jahnsen J, Dahal-Koirala S, Sollid LM. Chlubnová M, et al. Among authors: jahnsen j. Sci Adv. 2023 Jan 25;9(4):eade5800. doi: 10.1126/sciadv.ade5800. Epub 2023 Jan 25. Sci Adv. 2023. PMID: 36696493 Free PMC article.
Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome.
Kalla R, Adams AT, Nowak JK, Bergemalm D, Vatn S, Ventham NT, Kennedy NA, Ricanek P, Lindstrom J; IBD-Character Consortium; Söderholm J, Pierik M, D'Amato M, Gomollón F, Olbjørn C, Richmond R, Relton C, Jahnsen J, Vatn MH, Halfvarson J, Satsangi J. Kalla R, et al. Among authors: jahnsen j. J Crohns Colitis. 2023 Mar 18;17(2):170-184. doi: 10.1093/ecco-jcc/jjac127. J Crohns Colitis. 2023. PMID: 36029471 Free PMC article.
Human small intestine contains 2 functionally distinct regulatory T-cell subsets.
Chauhan SK, Bartolomé Casado R, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL. Chauhan SK, et al. Among authors: jahnsen j. J Allergy Clin Immunol. 2023 Jul;152(1):278-289.e6. doi: 10.1016/j.jaci.2023.02.030. Epub 2023 Mar 8. J Allergy Clin Immunol. 2023. PMID: 36893861 Free article.
130 results